Rejected at 3:49 p.m. Feb, 16, 2024 ] by herstein.jacob
Author: salmanumer
Related Note: 1484950460397
Rationale for change

fa 2023 pg 570
https://www.amboss.com/us/knowledge/opioids/
both sources place butorphanol and nalbuphine in same group with same mechanism of action i.e. kappa agonist and mew receptor partial agonist
acording to amboss pentazocine is a synthetic opioid that functions as an agonist at the kappa opioid receptors and sigma receptors with weak antagonist action at the mu opioid receptors.
i have also submitted changes to card about Pentazocine and nalbuphine and made it about butorphanol and nalbuphine(ankihub id b99430a4-ff84-4362-af13-0b66879d69f3)

Rejection reason

Overly complicated for incredibly low-yield topic. Per AMBOSS chart, current version of cards is accurate (nalbuphine and pentazocine can be antagonists or partial agonists, butorphanol is only partial agonist)

Text Text
Extra Extra
Lecture Notes
Empty field
Missed Questions
Empty field
Pathoma
Empty field
Boards and Beyond
Empty field
First Aid
Sketchy
Sketchy 2
Empty field
Sketchy Extra
Picmonic
Empty field
Pixorize
Physeo
Bootcamp
OME
Empty field
Additional Resources
Empty field
One by one
Empty field
#AK_Step1_v12::#B&B::02_Basic_Pharmacology::01_General::03_Dose-Response #AK_Step1_v12::#Bootcamp::Psychiatry::08_Substance_Misuse::04_Opioid_Classification #AK_Step1_v12::#AMBOSS::KPaUfk #AK_Step1_v12::#FirstAid::12_Neurology_and_Special_Senses::06_Pharm::16_Butorphanol_nalbuphine #AK_Step1_v12::#SketchyPharm::06_Neuro_&_Psych::01_Anesthetics_&_Analgesics::03_Opiates,_Naloxone,_Naltrexone #AK_Step1_v12::#OME::Clinical::Pediatrics/Psychiatry #AK_Other::Only_Step_1 #AK_Step1_v12::#Physeo::09_Pharm::14_Neuro::22_Mixed_Agonist_and_Antagonist_Opioids_(Nalbuphine_Pentazocine_Butorphanol) #AK_Step1_v12::#Pixorize::03_Pharmacology::16_Other_Neuro_Pharm::18_Partial_Opioid_Agonists #AK_Step1_v12::^Systems::Neuro::Pharmacology #AK_Other::#AK_Original_Decks::Step_1::Zanki_Pharmacology #AK_Step1_v12::#Bootcamp::Pharmacology::01_Pharmacodynamics::09_Drug-Receptor_Interactions #AK_Step1_v12::#Low/HighYield::2-RelativelyHighYield #AK_Step1_v12::#Physeo::^physeo_image_update #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::13_Medically_supervised_opioid_withdrawal_and_relapse_prevention #AK_Step1_v12::#FirstAid::12_Neurology_and_Special_Senses::06_Pharm::16_Butorphanol_nalbuphine::02_Clinical_Use::*Mixed_Agonist_&_Antagonist_Opioid_Analgesics::Butorphanol #AK_Step1_v12::#FirstAid::13_Psych::03_Pharm::13_Medically_supervised_opioid_withdrawal_and_relapse_prevention::02_Buprenorphine::*Butorphanol #AK_Step1_v12::#SketchyPharm::06_Neuro_&_Psych::01_Anesthetics_&_Analgesics::FA_Anesthetics #AK_Step1_v12::#Pixorize::^Missing_image